Decitabine

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

77 publications

Decitabine Chemical Structure

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Decitabine has been cited by 77 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M37vPGZ2dmO2aX;uJGF{e2G7 M3LwfVAvPcLizszN MorCNlQhcA>? MVP3ZZRmeg>? MUXtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> NIPXT2UzPTF{M{C4Ni=>
Eca109 NFTZWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITNSGIxNjVxMj61M|Uh|ryP MlrHNlQwPDhxN{KgbC=> M2XIVJdifGW{ NXXlU4RQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWSwWpp7OjVzMkOwPFI>
Eca109 MWDGeY5kfGmxbjDBd5NigQ>? NYTEbHc1OC53wrFOwG0> M{\2TVYwOTJxMkSgbC=> NXy1O5p3f2G2ZYK= MX\pcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi NWX5fYFlOjVzMkOwPFI>
Eca109 MVnGeY5kfGmxbjDBd5NigQ>? M2rkflAvPcLizszN MoOzNlQhcA>? M4HDWpdifGW{ NGj0UpJqdmirYnn0d{Bk\WyuIHnueoF{cW:w MlrwNlUyOjNyOEK=
Eca109 NVvBfIRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOwMlXDqM7:TR?= NHfpS4QzPCCq MoLre4F1\XJ? NUTIWoo{cW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? NVTtbWhXOjVzMkOwPFI>
Eca109 M2TDbWZ2dmO2aX;uJGF{e2G7 MoLlNE42NzFizszN M3K3Z|I1KGh? Mn3te4F1\XJ? NH7Id5Bl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ M2HYcVI2OTJ|MEiy
SW1116  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrOd2ZHOC53L{GvNk82KM7:TR?= MkPDOFghcA>? M{LGcWROW09? NF\1dolmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v M3XBOlI1QDd2Mki2
LOVO NYXuOWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPHNE42NzFxMj:1JO69VQ>? Ml71OFghcA>? M4P5TWROW09? M3S2eoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> MVKyOFg4PDJ6Nh?=
SW1116  NYqxO2trTnWwY4Tpc44hSXO|YYm= NXK2[I5POTBizszN MmOxOFghcA>? NWLCXWFmTE2VTx?= MnzSbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj NEDOcnIzPDh5NEK4Oi=>
LOVO M2i2fGZ2dmO2aX;uJGF{e2G7 M1foRlExKM7:TR?= Ml7GOFghcA>? NFXzR2NFVVOR MljSbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj M{LjTlI1QDd2Mki2
SW1116  MWrBdI9xfG:|aYOgRZN{[Xl? MkG1NVAh|ryP NEK5eYs1QCCq M3j2SGROW09? NHLVVllmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> MXuyOFg4PDJ6Nh?=
LOVO NV30PYNUSXCxcITvd4l{KEG|c3H5 M1jEPVExKM7:TR?= Mlf0OFghcA>? MknZSG1UVw>? Mm\D[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MonuNlQ5PzR{OE[=
RPMI-8226 MoD3RZBweHSxc3nzJGF{e2G7 MnvONU8zKM7:TR?= M3O2WlQ5Nzd{L{m2JIg> NEOwRXBFVVOR MmPXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUCyOFg{OzFyOB?=
OPM-2  NHj6doZCeG:ydH;zbZMhSXO|YYm= MoLrNU8zKM7:TR?= NYPsUYJvPzJxOU[vNVIxKGh? M4XsWmROW09? MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnnyNlQ5OzNzMEi=
JJN3  MoPXRZBweHSxc3nzJGF{e2G7 MUewMlUwOSEQvF2= NVrS[oR2OjRxNEigbC=> NE\JNJpFVVOR NH[2RVhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmT2NlQ5OzNzMEi=
NCI-H929  NXHISIFwSXCxcITvd4l{KEG|c3H5 NV\0XZlVOS9{IN88US=> MXO3Nk86Pi9zMkCgbC=> MVnEUXNQ NWjvPFRvcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M{XE[FI1QDN|MUC4
RPMI-8226 NEHiTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT4WYRbOS9{IN88US=> M2LNWFI1NzR6L{eyJIg> MojLSG1UVw>? MU\h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NIHrR2QzPDh|M{GwPC=>
OPM-2  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxM|Ih|ryP M3jRXVI1NzR6L{eyJIg> NGrpbm5FVVOR NVHpN5Bv[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NHL4UFQzPDh|M{GwPC=>
JJN3  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjQWWFKOC53L{Gg{txO MonaNlQwPDhxN{KgbC=> MXzEUXNQ MXHh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NXHL[npsOjR6M{OxNFg>
NCI-H929  MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfyNU8zKM7:TR?= Mkf6NlQwPDhxN{KgbC=> M33w[WROW09? M1zSO4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MXSyOFg{OzFyOB?=
HeLa MYDLbY5ie2ViQYPzZZk> NX\OVVdzU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NYfJUmtwOjR5OECwPVg>
HeLa NHnY[5BMcW6jc3WgRZN{[Xl? NWLWenVTU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz NX6yNZNlOjR5OECwPVg>
HeLa NGPpVo5McW6jc3WgRZN{[Xl? Ml;FT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> M3HzUFI1PzhyMEm4
HeLa M{j1UGtqdmG|ZTDBd5NigQ>? Mo\hT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NVLMOmRQOjR5OECwPVg>
NB4 MkHhSpVv[3Srb36gRZN{[Xl? M{fjeVIvPS93L{euOU8yOCEQvF2= MVuyOEBp NXfCNmdUTE2VTx?= NX3Rd5V1cW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? M2fmdlI1PDh2OEew
CD4+ CD25− T  M{\KNGZ2dmO2aX;uJGF{e2G7 NFfwZZMyNzVizszN M4PGNZJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NIK2flAzPDR5NkO2NC=>
BV-173 MknNRZBweHSxc3nzJGF{e2G7 MnPpNE4zPS9yLkWvNE44PS9zIN88US=> MkL6OFgwPzJxOU[gbC=> M4fGNuKhWEKV MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M2PIS|I1PDJ|NkGz
ML-1 MUnBdI9xfG:|aYOgRZN{[Xl? MUKwMlI2NzBwNT:wMlc2NzFizszN Mn3mOFgwPzJxOU[gbC=> MUhCpHBDWw>? NVHDW|E{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NWjkNlgxOjR2MkO2NVM>
HL-60 NEDzZ3JCeG:ydH;zbZMhSXO|YYm= NIPIN5YxNjJ3L{CuOU8xNjd3L{Gg{txO Moe0OFgwPzJxOU[gbC=> MWlCpHBDWw>? NELIVnhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MnvBNlQ1OjN4MUO=
KG-1a M4fYbGFxd3C2b4Ppd{BCe3OjeR?= MWqwMlI2NzBwNT:wMlc2NzFizszN M{PkeVQ5Nzd{L{m2JIg> NGfBUnHDqFCEUx?= Ml3DbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M1;XeVI1PDJ|NkGz
BV-173 MXLGeY5kfGmxbjDBd5NigQ>? M{iwOVI2OC93MEDuUS=> NHW2[|M1QCCq MURCpHBDWw>? MV7pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MoH6NlQ1OjN4MUO=
CEM NUm2c5I5TnWwY4Tpc44hSXO|YYm= MlzINlUxNzVyMH7N MX[0PEBp MVhCpHBDWw>? NVryXWdicW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MkfWNlQ1OjN4MUO=
HL-60 NVW0NFd1TnWwY4Tpc44hSXO|YYm= NXriOVA2OjVyL{WwNI5O MYm0PEBp NV;RfWlvyqCSQmO= M3jNPIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MYWyOFQzOzZzMx?=
ML-1 NFjuSoZHfW6ldHnvckBCe3OjeR?= Mn\0NlUxNzVyMH7N NIDXU|U1QCCq M2f5fOKhWEKV NWLuUY1lcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NITyPFQzPDR{M{[xNy=>
DLD-1 MX7GeY5kfGmxbjDBd5NigQ>? MmPsNlUxNzVyMH7N MnrKOFghcA>? NWXMc2VTyqCSQmO= MVHkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm M2rYT|I1PDJ|NkGz
HCT-116 Ml7iSpVv[3Srb36gRZN{[Xl? MUmyOVAwPTBybl2= NEHFNXM1QCCq MV1CpHBDWw>? NHnsenRldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MV2yOFQzOzZzMx?=
U937-A/E-9/14/18  NF7ySnNCeG:ydH;zbZMhSXO|YYm= MV2wMlAyNzBwMT:xM|ExKM7:TR?= MX60PEBp MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{nvcVI1OzByNEW2
HT29 NHuwfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG3NkBp M{PZSGlEPTB;MUSwNOKyOTd7IN88US=> NYPjcpZmOjRzN{KwOlE>
SW48 NVHEbFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG3NkBp MlfCTWM2OD1zNT6yxtE3NjJizszN MkewNlQyPzJyNkG=
HCT116 NGrtRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvVZ3I4OiCq NGHmdphKSzVyPUGuO:KyOC52IN88US=> NHzhN3YzPDF5MkC2NS=>
HepG2 NF30dWJHfW6ldHnvckBCe3OjeR?= MWWwMlUwOSEQvF2= M33RWVI1KGh? NFjzbZFFVVOR M1;BfpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NHXLV2gzPDF2Nki3OC=>
LS174T NVfIc|FrTnWwY4Tpc44hSXO|YYm= NWewT4l6OC53L{Gg{txO MUKyOEBp MUHEUXNQ MkHIcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= MojaNlQyPDZ6N{S=
HepG2 NXfsVolESXCxcITvd4l{KEG|c3H5 Mm\nNU8yOC9zMECg{txO M1;xOFch\A>? NEDlNppFVVOR MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{O0O|I1OTR4OEe0
LS174T NInEUGtCeG:ydH;zbZMhSXO|YYm= MX[xM|ExNzFyMDFOwG0> MlnTO{Bl MV7EUXNQ NV7pW4NMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYrN[lFVOjRzNE[4O|Q>
QBC-939 NFzWPYJCeG:ydH;zbZMhSXO|YYm= M2q0TVEwOTBxMUCwJO69VQ>? MofkO{Bl MknqSG1UVw>? MlTTbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWGyOFE1Pjh5NB?=
U251 NXHNcZJpSXCxcITvd4l{KEG|c3H5 M{XtUFEwOTBxMUCwJO69VQ>? NXPWTIlKPyCm NIXCT2pFVVOR NUXEdplpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEXxVZAzPDF2Nki3OC=>
HL-60 NWfydoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3XV4kyKM7:TR?= NYjYPJZtPDhiaB?= MkO5bY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? NI\KVngzPDByMEOyOC=>
MDA‑MB‑453 NIrKO2NHfW6ldHnvckBCe3OjeR?= MVywMlIwOSEQvF2= MkLCO|IhcA>? MV3jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M3nhbFI{QDR2MkK4
HCC1569 MlW3SpVv[3Srb36gRZN{[Xl? M2rGXlAvOi9zIN88US=> NXXTeHY5PzJiaB?= MY\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NHfvWIMzOzh2NEKyPC=>
BT‑474 MYfGeY5kfGmxbjDBd5NigQ>? NHTxN4kxNjJxMTFOwG0> MY[3NkBp NHvmVXNk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M{TVXlI{QDR2MkK4
AGS MXLBdI9xfG:|aYOgRZN{[Xl? MW[1M|ExNzJyL{WwJO69VQ>? M1TxN|Q5yqCqwrC= Mm\0SG1UVw>? MXTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MYWyN|U5Ojd6NB?=
A549 NXryZlhzSXCxcITvd4l{KEG|c3H5 NEDBcpQ2NzFyL{KwM|UxKM7:TR?= NXnZTWczPDkEoHlCpC=> NWL0OnAxTE2VTx?= NXPuVXpMcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MlTNNlM2QDJ5OES=
AGS  MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn3TYU2NzFyL{KwM|UxKM7:TR?= NWq5N3FQPDkEoHlCpC=> NEHBb3ZFVVOR MXvpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= MorBNlM2QDJ5OES=
Kasumi-1 NHi2Z3NCeG:ydH;zbZMhSXO|YYm= MXWwMlUh|ryP NGPNN4o1QMLiaNMg M1eyeIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NG\odmwzOzR7M{O0PC=>
OCI-AML3 NVPa[Gd1SXCxcITvd4l{KEG|c3H5 MXeyMlUh|ryP MmHxOFjDqGkEoB?= MnrU[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M{nWU|I{PDl|M{S4
MV4-11 MnLnRZBweHSxc3nzJGF{e2G7 MojqNk42KM7:TR?= MljWOFjDqGkEoB?= M3O2TYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MV6yN|Q6OzN2OB?=
NK  MlPHR5l1d3SxeHn0fUBCe3OjeR?= Mmm2NE4xOi1{MDFOwG0> NWPadnEzPSCm Mn7U[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NVXocVQ3OjN|MkiwPFg>
NK  MYTBdI9xfG:|aYOgRZN{[Xl? MoXuNE4xOi1{MDFOwG0> NYjYcmdPPSCm NXrBTHdz\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm NU\JTY43OjN|MkiwPFg>
NK  NGrPSVFHfW6ldHnvckBCe3OjeR?= MlLXNE4xOS1{MDFOwG0> NEDofVQ2KGR? Mm\6Z4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> M4KyelI{OzJ6MEi4
MOLT4/DNR MmGzSpVv[3Srb36gRZN{[Xl? NVzPd2FTPSEQvF2= Mn24OEBl MnjydoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> MXSyN|A3ODV5MB?=
Jurkat/DOX MojzSpVv[3Srb36gRZN{[Xl? NVnBeVNWPSEQvF2= M3\FVVQh\A>? M1HxRpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v M2jnbFI{ODZyNUew
MOLT4/DNR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf5c4xDPSEQvF2= M13YVlQh\A>? MnvadoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NVPESW0xOjNyNkC1O|A>
Jurkat/DOX M3XKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nuTVUh|ryP NFzUc|E1KGR? NHW2N2xz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MUOyN|A3ODV5MB?=
ccRCC  MmW2RZBweHSxc3nzJGF{e2G7 NHjTdI8xNjBzLUGw{txO NGTRZZE4OiCq MlPQSG1UVw>? NFjFcVFp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NYj3fFBxOjJ6Mk[0Olc>
TNBC  M4P2ZmFxd3C2b4Ppd{BCe3OjeR?= MUKwMlAyNTFyzszN NV;FNGo4PzJiaB?= NX\uPZJ6TE2VTx?= MofEbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? NGDpUnczOjh{NkS2Oy=>
A498 NFHnTJVCeG:ydH;zbZMhSXO|YYm= NYT6PW5UOC5yMT2xNO69VQ>? NILVOHo4OiCq NHvWNHVFVVOR MmTLbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MXiyNlgzPjR4Nx?=
KIJ265T M4XhcGFxd3C2b4Ppd{BCe3OjeR?= NYS3OZFsOC5yMT2xNO69VQ>? MVu3NkBp NFnrS3RFVVOR NF\HPI5qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MmjvNlI5OjZ2Nke=
MDA-231 MoDMRZBweHSxc3nzJGF{e2G7 MWKwMlAyNTFyzszN M3\WPVczKGh? NVnoW3RnTE2VTx?= M1;3bIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NHHIdJAzOjh{NkS2Oy=>
BT-20 NXrDfpl{SXCxcITvd4l{KEG|c3H5 NGL6U40xNjBzLUGw{txO MVi3NkBp NHLZd5RFVVOR MUjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M{L0elIzQDJ4NE[3
U937 M{m2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr4OU0zOCEQvF2= MV:yOE81QC95MjDo MWjpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M2rEeFIzPzZ5MEKx
HL60 M3TVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LwW|UuOjBizszN MWGyOE81QC95MjDo M2Daeolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NYLVc4xpOjJ5NkewNlE>
U937 NWX1VlNuSXCxcITvd4l{KEG|c3H5 MUKxOUDPxE1? NVWzWJQyOjRxNEivO|IhcA>? NESwUY9qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnLyNlI4PjdyMkG=
HL60 MlWxRZBweHSxc3nzJGF{e2G7 MYSxOUDPxE1? NUD3eY0zOjRxNEivO|IhcA>? MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXruU5lJOjJ5NkewNlE>
LS411N  M{\2PGFxd3C2b4Ppd{BCe3OjeR?= NYmwT5FXOC53IN88US=> NFvOR484OiCq NIHyb3lqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= MV:yNlQ3OTZ7NR?=
MDA-MB-231 Mn3iRZBweHSxc3nzJGF{e2G7 MWSxNEDPxE1? MkPzOFghcA>? M2P5dJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmHiNlE5QDd4OUe=
MCF-7  MnjyRZBweHSxc3nzJGF{e2G7 MYSxNEDPxE1? M13iOlQ5KGh? NGPzN41z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnXnNlE5QDd4OUe=
A375 NH34NYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyNE42KM7:TR?= MUGxM|UwQCCm MX\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NITtRpkzOTd7Nk[yNi=>
SKMEL1 M{nOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlryNE42KM7:TR?= MVWxM|UwQCCm NXi3XVZbcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MVGyNVc6PjZ{Mh?=
SKMEL3 NE\p[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnBdFNIOC53IN88US=> M2r1V|EwPS96IHS= MmTrbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NUK5SZZwOjF5OU[2NlI>
SKMEL28 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D6fVAvPSEQvF2= M2TySVEwPS96IHS= MVHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NXfqSXJMOjF5OU[2NlI>
MeWo NUD2NXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L3[lAvPSEQvF2= NG\tWZUyNzVxODDk NYDaOohIcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NYT2XGw4OjF5OU[2NlI>
B16 M3fuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXaNE42KM7:TR?= MUmxM|UwQCCm NXL3[2tTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NHruU20zOTd7Nk[yNi=>
Ly 1 NXi5d4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfhNlQhcA>? M4TMR2lEPTB;Nz6zJO69VQ>? MoPWNlE4PzJyNEm=
Ly 7 NULZeZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3GOpczPCCq MV\JR|UxRTFyLkeg{txO MV:yNVc4OjB2OR?=
Su-DHL6 NUjkR5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:yOEBp MXzJR|Ux97zgMkCg{txO M2L6OVIyPzd{MES5
Ly 10 NHi1OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2wNlQhcA>? MYjJR|Ux97zgMkCg{txO NXPScIRUOjF5N{KwOFk>
RIVA NXzFOVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKyOEBp NV3MPVQ6UUN3MP-8olIxKM7:TR?= NEL5T4MzOTd5MkC0PS=>
Su-DHL2 NIDKdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LJV|I1KGh? MkDiTWM2OO,:nkKwJO69VQ>? NFr4epUzOTd5MkC0PS=>
Ly 1 M4e5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r3d|Q5KGh? MVnJR|UxRTBwM{Sg{txO M2jtdFIyPzd{MES5
Ly 7 M1\uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn21OFghcA>? NXPCVm96UUN3ME2wMlAzPSEQvF2= NVTR[49{OjF5N{KwOFk>
Su-DHL6 M2PmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:0PEBp M17nUmlEPTExvK6yNEDPxE1? M1mxNVIyPzd{MES5
Ly 10 NHLxR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rCNlQ5KGh? MmTFTWM2OD1zLkig{txO MVOyNVc4OjB2OR?=
RIVA NH7KS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TWbVQ5KGh? NIHPdZNKSzVy78{eNlAh|ryP NWHaNYgyOjF5N{KwOFk>
Su-DHL2 NXva[mRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnJd3k1QCCq NWHSc2FnUUN3ME2xO{41KM7:TR?= M{nJOFIyPzd{MES5
Ly 1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPLO|IhcA>? NEXPdmVKSzVyPUCuNFEh|ryP NFfW[mkzOTd5MkC0PS=>
Ly 7 NX;NRpp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp M1HtTmlEPTB;MD6wNVgh|ryP MnnwNlE4PzJyNEm=
Su-DHL6 NGTCSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3zO|IhcA>? M{S3[2lEPTB;MT62JO69VQ>? NXz1W402OjF5N{KwOFk>
Ly 10 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;UTYQ4OiCq MWLJR|UxRTFwMjFOwG0> Mnn0NlE4PzJyNEm=
RIVA M4r1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33DWFczKGh? MkXBTWM2OO,:nkKwJO69VQ>? M1ftTVIyPzd{MES5
Su-DHL2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGO|IhcA>? NFLKOoZKSzVyPUGxMlIh|ryP MWmyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID